Imprimis Pharmaceuticals, Inc. (IMMY) has 8 open-market insider trades by 6 insiders since 2015. The most active filer is Opaleye Management Inc., 10% Owner.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Donald Paul Miloni | 10% | — | 1 | $3.3M | 2015-05-19 |
| Opaleye Management Inc. | 10% Owner | — | 3 | $461K | 2016-03-11 |
| Robert J. Kammer | Dir | — | 1 | $390K | 2018-12-03 |
| Mark L. Baum | CEO | — | 1 | $279K | 2016-12-19 |
| Richard L. Lindstrom M.D. | Dir | — | 1 | $179K | 2017-04-27 |
| Andrew R. Boll | CFO | — | 1 | $70K | 2018-02-01 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Robert J. Kammer | Director | Sell | $46K | 2018-12-03 |
| Robert J. Kammer | Director | Sell | $42K | 2018-11-01 |
| Robert J. Kammer | Director | Sell | $30K | 2018-10-15 |
| Robert J. Kammer | Director | Sell | $30K | 2018-09-04 |
| Robert J. Kammer | Director | Sell | $390K | 2018-08-10 |
| Robert J. Kammer | Director | Sell | $31K | 2017-07-17 |
Companies that share insiders with IMMY, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Andrew R. Boll | CFO | Buy | $70K | 2016-12-19 |
| Mark L. Baum | CEO | Buy | $279K | 2016-12-19 |
| Richard L. Lindstrom M.D. | Director | Buy | $179K | 2016-12-19 |
| Opaleye Management Inc. | 10% Owner | Buy | $162K | 2016-03-11 |
| Opaleye Management Inc. | 10% | Buy | $277K | 2015-06-30 |
| Opaleye Management Inc. | 10% | Buy | $22K | 2015-05-19 |
| Donald Paul Miloni | 10% | Sell | $3.3M | 2015-05-18 |